Cornelia Calcii
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Cornelia Calcii has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Svetlana Hadjiu
State University of Medicine and Pharmacy „Nicolae Testemiţanu”, Chisinau, Republic of Moldova
4 shared publications - Mariana Sprincean
State University of Medicine and Pharmacy „Nicolae Testemiţanu”, Chisinau, Republic of Moldova
3 shared publications - Stanislav Groppa
Nicolae Testemitanu State University of Medicine and Pharmacy
3 shared publications Corina Griu
2 shared publicationsLudmila Feghiu
2 shared publications- Ludmila Feghiu
National Epilepsy Center, Chisinau, Republic of Moldova
2 shared publications
Latest Publications
- 1 October 2022
- Published by Periodic Publication Moldovan Journal of Health Sciences in Moldovan Journal of Health Sciences
- Vol. 29 (3) , 44-49
Molecular and cellular biomarkers in status epilepticus and epilepsy
Introduction. Peripheral biomarkers have numerous uses in the treatment, prognosis, and pharmacovigilance of epilepsy. Unfortunately, no peripheral biomarker has demonstrated proven efficacy, although several options are being investigated. In this article, we want to analyze the main areas in which peripheral biomarkers can present their usefulness, including participation in the processes of inflammation, dysfunction of the blood-brain barrier, changes in metabolism, hormones, and growth factors. Material and methods. Publications on diagnostic biomarkers of epilepsy were reviewed. References were identified by PubMed, MEDLINE and Scopus search until June 2022, with various combinations of the terms – „epilepsy”, „seizures”, „epileptogenesis”, „biomarkers”, „neuroimaging”, „inflammation”, „status epilepticus”, „prognosis”. A qualitative and analytical study was performed focused on primary studies published in 2020-2022. More than 85 sources were identified and 33 were selected for analysis from the PubMed, MEDLINE, and Scopus online databases. 12 articles, 5 clinical trials, 2 meta-analyses, 7 reviews, and 7 systematic reviews were identified. Results. Screening articles from online databases according to the search criteria, we found 258 titles on molecular and cellular biomarkers in epilepsy highlighted. The final bibliography included 33 sources that summarized that biomarkers of epileptogenesis are expensive and difficult to research, but the identification of biomarkers specific to the entire epileptogenic process, in close proximity to neuronal damage, have demonstrated the possibility of predicting the risk of seizures, epilepsy and resistance to treatment. Conclusions. Epilepsy remains a continuous area of research; a special role is occupied by specific biomarkers of great clinical importance, being necessary for the prognosis of the disease, the risk of neurological sequelae, refractory to anti-epileptic drugs. Thus, their identification could have a significant impact on the clinical course of the disease.
- 1 October 2022
- Published by Periodic Publication Moldovan Journal of Health Sciences in Moldovan Journal of Health Sciences
- Vol. 29 (3) , 44-49
Molecular and cellular biomarkers in status epilepticus and epilepsy
Introduction. Peripheral biomarkers have numerous uses in the treatment, prognosis, and pharmacovigilance of epilepsy. Unfortunately, no peripheral biomarker has demonstrated proven efficacy, although several options are being investigated. In this article, we want to analyze the main areas in which peripheral biomarkers can present their usefulness, including participation in the processes of inflammation, dysfunction of the blood-brain barrier, changes in metabolism, hormones, and growth factors. Material and methods. Publications on diagnostic biomarkers of epilepsy were reviewed. References were identified by PubMed, MEDLINE and Scopus search until June 2022, with various combinations of the terms – „epilepsy”, „seizures”, „epileptogenesis”, „biomarkers”, „neuroimaging”, „inflammation”, „status epilepticus”, „prognosis”. A qualitative and analytical study was performed focused on primary studies published in 2020-2022. More than 85 sources were identified and 33 were selected for analysis from the PubMed, MEDLINE, and Scopus online databases. 12 articles, 5 clinical trials, 2 meta-analyses, 7 reviews, and 7 systematic reviews were identified. Results. Screening articles from online databases according to the search criteria, we found 258 titles on molecular and cellular biomarkers in epilepsy highlighted. The final bibliography included 33 sources that summarized that biomarkers of epileptogenesis are expensive and difficult to research, but the identification of biomarkers specific to the entire epileptogenic process, in close proximity to neuronal damage, have demonstrated the possibility of predicting the risk of seizures, epilepsy and resistance to treatment. Conclusions. Epilepsy remains a continuous area of research; a special role is occupied by specific biomarkers of great clinical importance, being necessary for the prognosis of the disease, the risk of neurological sequelae, refractory to anti-epileptic drugs. Thus, their identification could have a significant impact on the clinical course of the disease.
- Open Access
- 31 January 2022
- Published by MDPI AG in Brain Sciences
- Vol. 12 (2) , 198
Emerging Treatments for Disorders of Consciousness in Paediatric Age
The number of paediatric patients living with a prolonged Disorder of Consciousness (DoC) is growing in high-income countries, thanks to substantial improvement in intensive care. Life expectancy is extending due to the clinical and nursing management achievements of chronic phase needs, including infections. However, long-known pharmacological therapies such as amantadine and zolpidem, as well as novel instrumental approaches using direct current stimulation and, more recently, stem cell transplantation, are applied in the absence of large paediatric clinical trials and rigorous age-balanced and dose-escalated validations. With evidence building up mainly through case reports and observational studies, there is a need for well-designed paediatric clinical trials and specific research on 0–4-year-old children. At such an early age, assessing residual and recovered abilities is most challenging due to the early developmental stage, incompletely learnt motor and cognitive skills, and unreliable communication; treatment options are also less explored in early age. In middle-income countries, the lack of rehabilitation services and professionals focusing on paediatric age hampers the overall good assistance provision. Young and fast-evolving health insurance systems prevent universal access to chronic care in some countries. In low-income countries, rescue networks are often inadequate, and there is a lack of specialised and intensive care, difficulty in providing specific pharmaceuticals, and lower compliance to intensive care hygiene standards. Despite this, paediatric cases with DoC are reported, albeit in fewer numbers than in countries with better-resourced healthcare systems. For patients with a poor prospect of recovery, withdrawal of care is inhomogeneous across countries and still heavily conditioned by treatment costs as well as ethical and cultural factors, rather than reliant on protocols for assessment and standardised treatments. In summary, there is a strong call for multicentric, international, and global health initiatives on DoC to devote resources to the paediatric age, as there is now scope for funders to invest in themes specific to DoC affecting the early years of the life course.
- 31 January 2022
- Published by MDPI AG in Brain Sciences
- Vol. 12 (2) , 198
Open AccessEmerging Treatments for Disorders of Consciousness in Paediatric Age
The number of paediatric patients living with a prolonged Disorder of Consciousness (DoC) is growing in high-income countries, thanks to substantial improvement in intensive care. Life expectancy is extending due to the clinical and nursing management achievements of chronic phase needs, including infections. However, long-known pharmacological therapies such as amantadine and zolpidem, as well as novel instrumental approaches using direct current stimulation and, more recently, stem cell transplantation, are applied in the absence of large paediatric clinical trials and rigorous age-balanced and dose-escalated validations. With evidence building up mainly through case reports and observational studies, there is a need for well-designed paediatric clinical trials and specific research on 0–4-year-old children. At such an early age, assessing residual and recovered abilities is most challenging due to the early developmental stage, incompletely learnt motor and cognitive skills, and unreliable communication; treatment options are also less explored in early age. In middle-income countries, the lack of rehabilitation services and professionals focusing on paediatric age hampers the overall good assistance provision. Young and fast-evolving health insurance systems prevent universal access to chronic care in some countries. In low-income countries, rescue networks are often inadequate, and there is a lack of specialised and intensive care, difficulty in providing specific pharmaceuticals, and lower compliance to intensive care hygiene standards. Despite this, paediatric cases with DoC are reported, albeit in fewer numbers than in countries with better-resourced healthcare systems. For patients with a poor prospect of recovery, withdrawal of care is inhomogeneous across countries and still heavily conditioned by treatment costs as well as ethical and cultural factors, rather than reliant on protocols for assessment and standardised treatments. In summary, there is a strong call for multicentric, international, and global health initiatives on DoC to devote resources to the paediatric age, as there is now scope for funders to invest in themes specific to DoC affecting the early years of the life course.
- 1 September 2021
- Published by State Enterprise "Revista Curier Medical" in The Moldovan Medical Journal
- Vol. 64 (3) , 28-31
Brain imaging of children with postischemic seizures
Background: Arterial ischemic stroke is a rare disease found in the pediatric population, with an incidence of 2-13 out of 100000 children per year. Children develop seizures more often in the initial phase of stroke compared to adults. Material and methods: There have been included children examined by brain MRI hospitalized in the department of neurology (early aged children), Hospital of Mother and Child Health Care, with a diagnose of ischemic stroke, with an acute focal neurological syndrome installed. The children not having an imagistic confirmation of arterial ischemic stroke were excluded. Results: The study lot was composed of 78 children, who corresponded to all the inclusion criteria for this study (Tab.1). The children were examined by 1.5T and 3T MRI with multiplanar assessment of brain structures. In cases with acute / subacute stroke specific diffusion sequences (DWI and ADC) were applied to determine the type of stroke, approximate installation period. Ischemic brain lesions on MRI are presented by areas of cytotoxic edema in acute/ subacute cases, in chronic / late cases by the appearance of changes such as lacunar defects, areas of encephalomalacia. Conclusions: The vast majority of children with brain lesions on MRI have convulsions with early onset and have developed recurrent seizures after the acute phase of stroke.
- 1 September 2021
- Published by State Enterprise "Revista Curier Medical" in The Moldovan Medical Journal
- Vol. 64 (3) , 28-31
Brain imaging of children with postischemic seizures
Background: Arterial ischemic stroke is a rare disease found in the pediatric population, with an incidence of 2-13 out of 100000 children per year. Children develop seizures more often in the initial phase of stroke compared to adults. Material and methods: There have been included children examined by brain MRI hospitalized in the department of neurology (early aged children), Hospital of Mother and Child Health Care, with a diagnose of ischemic stroke, with an acute focal neurological syndrome installed. The children not having an imagistic confirmation of arterial ischemic stroke were excluded. Results: The study lot was composed of 78 children, who corresponded to all the inclusion criteria for this study (Tab.1). The children were examined by 1.5T and 3T MRI with multiplanar assessment of brain structures. In cases with acute / subacute stroke specific diffusion sequences (DWI and ADC) were applied to determine the type of stroke, approximate installation period. Ischemic brain lesions on MRI are presented by areas of cytotoxic edema in acute/ subacute cases, in chronic / late cases by the appearance of changes such as lacunar defects, areas of encephalomalacia. Conclusions: The vast majority of children with brain lesions on MRI have convulsions with early onset and have developed recurrent seizures after the acute phase of stroke.
- 1 June 2021
- Published by Moldova State University
- Vol. Ediția 11, 61
Enzyme immunoassay parameters in ischemic stroke in children
- 1 June 2021
- Published by Moldova State University
- Vol. Ediția 11, 61
Enzyme immunoassay parameters in ischemic stroke in children
- 1 May 2021
- Published by State Enterprise "Revista Curier Medical" in The Moldovan Medical Journal
- Vol. 64 (2) , 12-15
Refractory status epilepticus – a major problem for the practitioners
Introduction: Status epilepticus (SE) is a life-threatening neurological emergency requiring immediate medical intervention and is associated with high mortality and morbidity. The aim of this research was evaluation of clinical and etiological profile of refractory status epilepticus (RSE) among children aged between 1 month and 18 years. Material and methods: The study was done between January 1, 2017 and December 24, 2019. All children with the age limits mentioned above, who presented convulsive SE, subsequently with development in refractory status epileptic (RSE), were included in the study. Patients were investigated and evaluated according to a standard protocol. Subsequently, the characteristics of children with RSE and those without an evolution in RSE were compared. Results: 55 children, out of whom 32 boys with SE were enrolled in the study, of which 20 children (36%) developed RSE. Central nervous system (CNS) infections were the most common causes of SE and development of RSE (51% in SE and 53% in RSE, p > 0.05). Noncompliance of antiepileptic medication served as the second cause for evolution of RSE. The overall mortality rate was 10.9%, the chances of death in RSE (20%) being higher than in SE (5.7%). The unfavorable prognosis was seven times higher in children with RSE, compared to children who developed SE. Conclusions: In the management of CNS infections, pediatricians should be aware of the high risk of developing RSE. In addition, the possibility of developing RSE should be considered and promptly managed in an intensive care unit in order to reduce the risk of mortality and morbidity of this severe neurological condition
- 1 May 2021
- Published by State Enterprise "Revista Curier Medical" in The Moldovan Medical Journal
- Vol. 64 (2) , 12-15
Refractory status epilepticus – a major problem for the practitioners
Introduction: Status epilepticus (SE) is a life-threatening neurological emergency requiring immediate medical intervention and is associated with high mortality and morbidity. The aim of this research was evaluation of clinical and etiological profile of refractory status epilepticus (RSE) among children aged between 1 month and 18 years. Material and methods: The study was done between January 1, 2017 and December 24, 2019. All children with the age limits mentioned above, who presented convulsive SE, subsequently with development in refractory status epileptic (RSE), were included in the study. Patients were investigated and evaluated according to a standard protocol. Subsequently, the characteristics of children with RSE and those without an evolution in RSE were compared. Results: 55 children, out of whom 32 boys with SE were enrolled in the study, of which 20 children (36%) developed RSE. Central nervous system (CNS) infections were the most common causes of SE and development of RSE (51% in SE and 53% in RSE, p > 0.05). Noncompliance of antiepileptic medication served as the second cause for evolution of RSE. The overall mortality rate was 10.9%, the chances of death in RSE (20%) being higher than in SE (5.7%). The unfavorable prognosis was seven times higher in children with RSE, compared to children who developed SE. Conclusions: In the management of CNS infections, pediatricians should be aware of the high risk of developing RSE. In addition, the possibility of developing RSE should be considered and promptly managed in an intensive care unit in order to reduce the risk of mortality and morbidity of this severe neurological condition
- 1 May 2021
- Published by State Enterprise "Revista Curier Medical" in The Moldovan Medical Journal
- Vol. 64 (2) , 5-11
Ischemic stroke in children depending on risk factors
Background: Ischemic stroke (IS) in children is a major neuropediatric emergency. The incidence of stroke in children is from 2 to 13 for 100000 children. IS in perinatal period occurs in 1 for 2300 – 5000 live births. Material and methods: In 2010 – 2019 in the Republic of Moldova was carried out a retrospective as well as prospective study on a cohort of 458 children diagnosed with stroke. Were studied possible risk factors related to IS. Out of 458 children, 284 children with IS were selected and diagnosed during the reference period. Results: IS was determined in 284 cases with the diagnosis of stroke (62%, 95CI 59.73-64.27). Among the most common risk factors for the development of neonatal IS are pathologies of amniotic membranes in 113 cases (39.8%, 95CI 36.9-42.7), pathologies of amniotic fluid with meconium in 135 cases (47.5%, 95CI 44.54-50.46), and history of urgent caesarean section in 132 cases (46.5%, 95CI 43.54-49.46). Among the etiological causes of IS in the studied children were: congenital heart anomalies in 52 cases (18.3%, 95CI 16.01-20.59), neonatal encephalopathy in 27 cases (9.5%, 95CI 7.76-11.24), genetic syndromes in 18 cases (6.3%, 95CI 4.85-7.75), sickle cell disease – 5 (1.8%, 95CI 1.06–2.54), MELAS syndrome – 4 (1.4%, 95CI 0.7-2.1). Conclusions: IS risk factors are an important problem in clinical research. Most often, there is not a single risk factor responsible for the development of IS in children
- 1 May 2021
- Published by State Enterprise "Revista Curier Medical" in The Moldovan Medical Journal
- Vol. 64 (2) , 5-11
Ischemic stroke in children depending on risk factors
Background: Ischemic stroke (IS) in children is a major neuropediatric emergency. The incidence of stroke in children is from 2 to 13 for 100000 children. IS in perinatal period occurs in 1 for 2300 – 5000 live births. Material and methods: In 2010 – 2019 in the Republic of Moldova was carried out a retrospective as well as prospective study on a cohort of 458 children diagnosed with stroke. Were studied possible risk factors related to IS. Out of 458 children, 284 children with IS were selected and diagnosed during the reference period. Results: IS was determined in 284 cases with the diagnosis of stroke (62%, 95CI 59.73-64.27). Among the most common risk factors for the development of neonatal IS are pathologies of amniotic membranes in 113 cases (39.8%, 95CI 36.9-42.7), pathologies of amniotic fluid with meconium in 135 cases (47.5%, 95CI 44.54-50.46), and history of urgent caesarean section in 132 cases (46.5%, 95CI 43.54-49.46). Among the etiological causes of IS in the studied children were: congenital heart anomalies in 52 cases (18.3%, 95CI 16.01-20.59), neonatal encephalopathy in 27 cases (9.5%, 95CI 7.76-11.24), genetic syndromes in 18 cases (6.3%, 95CI 4.85-7.75), sickle cell disease – 5 (1.8%, 95CI 1.06–2.54), MELAS syndrome – 4 (1.4%, 95CI 0.7-2.1). Conclusions: IS risk factors are an important problem in clinical research. Most often, there is not a single risk factor responsible for the development of IS in children
- Open Access
- 6 November 2019
- Published by European Scientific Center Biological Marker s.r.o. in Biological Markers in Fundamental and Clinical Medicine (collection of abstracts)
- Vol. 3 (1) , 101-102
CILIARY NEUROTROPHIC FACTOR IN PATIENTS WITH PEDIATRIC ISCHEMIC STROKE
CILIARY NEUROTROPHIC FACTOR IN PATIENTS WITH PEDIATRIC ISCHEMIC STROKE
- 6 November 2019
- Published by European Scientific Center Biological Marker s.r.o. in Biological Markers in Fundamental and Clinical Medicine (collection of abstracts)
- Vol. 3 (1) , 101-102
Open AccessCILIARY NEUROTROPHIC FACTOR IN PATIENTS WITH PEDIATRIC ISCHEMIC STROKE
CILIARY NEUROTROPHIC FACTOR IN PATIENTS WITH PEDIATRIC ISCHEMIC STROKE
- 1 August 2018
- Published by Elsevier in Autoimmunity Reviews
- Vol. 17 (8) , 755-767
Antiphospholipid antibodies in epilepsy: A systematic review and meta-analysis
- 1 August 2018
- Published by Elsevier in Autoimmunity Reviews
- Vol. 17 (8) , 755-767
Antiphospholipid antibodies in epilepsy: A systematic review and meta-analysis